- Trials with a EudraCT protocol (176)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
176 result(s) found for: Conduct Disorders.
Displaying page 1 of 9.
EudraCT Number: 2010-021884-34 | Sponsor Protocol Number: PERS3 | Start Date*: 2013-01-24 | |||||||||||
Sponsor Name:Radboud University Medical Centre Nijmegen | |||||||||||||
Full Title: Relapse prevention in children and adolescents with DSM-IV Conduct Disorder treated with Risperidone: a Randomized Double blind, Placebo-Controlled, Discontinuation Study. | |||||||||||||
Medical condition: Conduct Disorder DSM-IV-TR; 312.8x, APA 2000 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000567-26 | Sponsor Protocol Number: 2010-021883-14 | Start Date*: 2013-01-31 | |||||||||||
Sponsor Name:Radboud University Medical Centre Nijmegen | |||||||||||||
Full Title: A randomized double-blind, placebo-controlled study of risperidone in the treatment of DSM-IV-TR conduct disorder in children and adolescents. | |||||||||||||
Medical condition: Conduct Disorder DSM-IV-TR; 312.8x¸ APA, 2000 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-009475-35 | Sponsor Protocol Number: III.04.0904 | Start Date*: 2009-09-10 | |||||||||||||||||||||
Sponsor Name:KARAKTER universitair centrum voor kinder- en jeudpsychiatrie | |||||||||||||||||||||||
Full Title: Lack of Empathy as a Symptom in various Psychiatric Disorders | |||||||||||||||||||||||
Medical condition: Autism Spectrum Disorder (Autism, Asperger's Syndrome) Conduct Disorder Mild Mental Retardation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002207-13 | Sponsor Protocol Number: NRA1280023 | Start Date*: 2006-06-29 |
Sponsor Name:Dept. Child & Adolescent Psychiatry Univ. Freiburg | ||
Full Title: Ziprasidone for severe conduct and other disruptive behavior disorders in children and adolescents – a placebo controlled, randomized, double blind clinical trial | ||
Medical condition: conduct disorder (CD), oppositional defiant disorder (ODD) and disruptive behavior disorder not otherwise specified (DBD-NOS) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-000048-10 | Sponsor Protocol Number: CCAD106A2101 | Start Date*: 2005-04-20 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A 52-week, multi-center, randomized, double-blind, placebo-controlled, time-lagged, parallel group study in patients with mild to moderate Alzheimer's Disease (AD) to investigate the safety, tolera... | ||
Medical condition: Alzheimer's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004420-30 | Sponsor Protocol Number: CL3-95008-002 | Start Date*: 2018-10-04 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo controlled mult... | |||||||||||||
Medical condition: Autism Spectrum Disorder (ASD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) NL (Not Authorised) HU (Completed) PT (Completed) PL (Prematurely Ended) IE (Prematurely Ended) CZ (Completed) SK (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001456-29 | Sponsor Protocol Number: Mino-TRD(OptiMD) | Start Date*: 2015-09-23 |
Sponsor Name:Charité - Universitätsmedizin Berlin | ||
Full Title: A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Treatment Resistant Unipolar Major Depressive Disorder (MDD) | ||
Medical condition: Minocycline, a broad-spectrum and central nervous system entering tetracycline, reduces within an additional therapy the symptomatology of depressive patients. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-000749-21 | Sponsor Protocol Number: 4.20 | Start Date*: 2016-03-14 |
Sponsor Name:Medizinische Hochschule Hannover | ||
Full Title: Botulinumtoxin A for emotional stabilization in borderline personality disorder | ||
Medical condition: Borderline personality disorder | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000930-37 | Sponsor Protocol Number: STEMQUIRI/12ES01 | Start Date*: 2014-04-29 | |||||||||||
Sponsor Name:Laboratorios Salvat, S.A. | |||||||||||||
Full Title: A phase II clinical trial to assess the effect of HC-SVT-1001 (autologous fat stem adult mesenchymal cells expanded and combined with a tricalcium phosphate biomaterial) and HC-SVT-1002 (allogeneic... | |||||||||||||
Medical condition: Atrophic pseudarthrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000957-37 | Sponsor Protocol Number: AS0013 | Start Date*: 2017-09-25 | |||||||||||
Sponsor Name:UCB Biopharma SRL | |||||||||||||
Full Title: A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects with Active Ankylo... | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) GR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005028-10 | Sponsor Protocol Number: FARM7PER7 | Start Date*: 2008-10-14 | |||||||||||
Sponsor Name:Universita' di Firenze; Dipartimento di Farmacologia Preclinica e Clinica | |||||||||||||
Full Title: Methadone dose adjustments, plasma R-methadone levels and therapeutic outcome of opioid addiction | |||||||||||||
Medical condition: Heroin dependence | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004419-38 | Sponsor Protocol Number: CL3-95008-001 | Start Date*: 2018-10-04 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, place... | |||||||||||||
Medical condition: Autism Spectrum Disorder (ASD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Completed) ES (Prematurely Ended) NL (Completed) HU (Completed) PT (Completed) PL (Prematurely Ended) IT (Completed) IE (Prematurely Ended) CZ (Ongoing) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001630-33 | Sponsor Protocol Number: MEM-MD-69 | Start Date*: 2012-11-14 | |||||||||||||||||||||
Sponsor Name:Forest Research Institute, Inc | |||||||||||||||||||||||
Full Title: An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients with Autism, Asperger’s Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) | |||||||||||||||||||||||
Medical condition: Autism or Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated with Memantine | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) NL (Ongoing) EE (Completed) FR (Ongoing) IS (Prematurely Ended) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001523-39 | Sponsor Protocol Number: D1050300 | Start Date*: 2013-11-08 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A PHASE 1 OPEN-LABEL, MULTICENTER, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF LURASIDONE IN SUBJECTS 6 TO 17 YEARS OLD WITH SCHIZOPHRENIA SPE... | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001568-31 | Sponsor Protocol Number: MEM-MD-68 | Start Date*: 2012-11-14 | |||||||||||||||||||||
Sponsor Name:Forest Research Institute, Inc | |||||||||||||||||||||||
Full Title: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder ... | |||||||||||||||||||||||
Medical condition: Autism or Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated with Memantine | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) NL (Ongoing) EE (Completed) FR (Ongoing) IT (Completed) IS (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005026-21 | Sponsor Protocol Number: 1403740 | Start Date*: 2012-01-31 | |||||||||||
Sponsor Name:KYTHERA Biopharmaceuticals, Inc. | |||||||||||||
Full Title: Long-term, follow-up study of subjects who completed phase III trials ATX-101-10-16 or ATX-101-10-17 (sodium deoxycholate injection) for the reduction of localized subcutaneous fat in the submental... | |||||||||||||
Medical condition: Reduction of subcutaneous fat in the submental area | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001518-40 | Sponsor Protocol Number: 848040001 | Start Date*: 2020-01-31 |
Sponsor Name:VU Medical Center | ||
Full Title: Netherlands study of Optimal, PERsonalized Antidepressant use (OPERA-DISCONTINUATION) | ||
Medical condition: Depression | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003745-11 | Sponsor Protocol Number: 1346-0014 | Start Date*: 2021-11-16 | |||||||||||
Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG | |||||||||||||
Full Title: An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) ES (Ongoing) SK (Ongoing) HU (Ongoing) NO (Ongoing) DK (Ongoing) LT (Ongoing) IT (Ongoing) GR (Ongoing) SE (Ongoing) NL (Ongoing) FI (Ongoing) HR (Ongoing) AT (Ongoing) BG (Ongoing) PT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001616-33 | Sponsor Protocol Number: MEM-MD-91 | Start Date*: 2012-11-14 | |||||||||||||||||||||
Sponsor Name:Forest Research Institute, Inc. | |||||||||||||||||||||||
Full Title: An Open-Label Study Of The Safety And Tolerability Of Memantine In Pediatric Patients With Autism, Asperger’s Disorder, Or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) | |||||||||||||||||||||||
Medical condition: Autism or Asperger’s Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) NL (Ongoing) EE (Completed) IS (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005260-41 | Sponsor Protocol Number: SA652012 | Start Date*: 2016-10-13 | |||||||||||
Sponsor Name:Academic Medical Centre | |||||||||||||
Full Title: Efficacy of optimized thiopurine therapy in ulcerative colitis. | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.